Developing treatments to counteract fentanyl overdose
Synthetic Scavenger Medical Countermeasures for Fentanyl
This study is testing a new treatment using special antibodies that could help quickly neutralize fentanyl in the body, aiming to provide a better option for people who might experience an overdose from this powerful opioid.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sri International NIH-funded |
| Lab location | 1 site (Menlo Park, United States) |
| Project ID | NIH-10852933 on NIH RePORTER |
What this research studies
This research focuses on creating synthetic scavenger medical countermeasures to combat the effects of fentanyl, a potent synthetic opioid responsible for numerous overdose deaths. The approach involves using monoclonal antibodies that can neutralize fentanyl in the bloodstream, potentially offering a more effective treatment than current options like naloxone. By investigating the efficacy of these antibodies, the research aims to provide a solution for both immediate treatment and prevention of opioid toxicity. Patients may benefit from a more reliable and efficient antidote to fentanyl overdoses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk of opioid overdose, particularly those using fentanyl or similar synthetic opioids.
Not a fit: Patients who do not use opioids or are not at risk of opioid overdose may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, more effective treatment for fentanyl overdoses, potentially saving lives.
How similar studies have performed: Previous research has shown that monoclonal antibodies can effectively neutralize potent opioids in animal models, indicating promise for this approach.
Where this research is happening
Menlo Park, United States
- Sri International — Menlo Park, United States (Active)
Researchers
- Principal investigator: Liu, Xiaohe — Sri International
- Study coordinator: Liu, Xiaohe
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.